Mason Freeman
Venture Partner @ 5AM Ventures
Boston, United States
Mason Freeman is a Series A investor at 5AM Ventures in Boston focused on Health Care and Therapeutics. Mason Freeman, M.D. joined 5AM Ventures as a Scientific Advisor in 2007 and became a Venture Partner in 2008. He serves as Chief of the Lipid Metabolism Unit and Director of Translational Medicine at Massachusetts General Hospital (MGH), Harvard Medical School. Dr. Freeman currently serves as clinical advisor to Relypsa and previously served asBoard Director for Envoy (acquired by Takeda). Trained in internal medicine and endocrinology, Dr. Freeman has spent twenty years studying the trafficking of cholesterol into and out of macrophages. As a post-doctoral research fellow in the Biology Department at MIT he cloned the first macrophage scavenger receptor to be molecularly identified. In 1992 he became Chief of the MGH’s Lipid Metabolism Unit, which he continues to direct as well as the Translational Medicine programs at the MGH Center for Computational and Integrative Biology and the MGH Clinical Research Program. In these roles he oversees a basic science research laboratory devoted to studying lipid trafficking as well as a clinical investigative team developing a novel oral anti-diabetic drug.
- Total investments:
- 1
- Last investment:
- Lead investor:
- 100%
Last updated:
For AI agents: llms.txt
Industries Mason Freeman invests in
Stages Mason Freeman invests in
Countries Mason Freeman invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Health Care 1 (100%)
- Therapeutics 1 (100%)
- Biotechnology 1 (100%)
- Pharmaceutical 1 (100%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Crinetics Pharmaceuticals discovers and develops novel therapeutics targeting peptide hormone receptors for the treatment of endocrine-related diseases and cancers. Their programs are derived from internal discovery efforts and use objective hormonal biomarker endpoints for preclinical and clinical studies to reduce both the risk and cost toachieve meaningful clinical data. Crinetics is seeking motivated partners to help advance Their programs to become commercially successful products. | $40M / Series A / Nov 02, 2015 |
Co-Investors
About 5AM Ventures
5AM Ventures is a venture capital firm that offers seed- and early-stage investments to its clients. The company’s client portfolio consists of firms in the biopharmaceutical, life sciences, medical technology, and research instrument industries. 5AM Ventures was founded in 2002 by John Diekman and Andrew Schwab and is based in California.
5AM Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
John Diekman
Founder & Managing Partner
|
|||
Kush Parmar
Managing Partner
|
|||
|
Mason Freeman
Venture Partner
|
|||
Richard J. Ulevitch
Venture Partner
|
|||
Scott Rocklage
Founding Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Mason Freeman invest in?
Mason Freeman invests primarily in Health Care, Therapeutics and Biotechnology startups, most often at Series A stage. Most of the 1 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Mason Freeman?
Public channels for Mason Freeman include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Mason Freeman last invest?
The most recent investment recorded for Mason Freeman closed in Nov 2015. Shizune tracks 1 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
